246P Palbociclib dose patterns in Swedish patients with metastatic breast cancer: Evidence from the SIRI study
Antonis Valachis(Örebro University Hospital), Maria Jakobsson(Pfizer (Sweden)), Mathias Lilja(Quantify Research (Sweden)), Hanna Fues Wahl(Quantify Research (Sweden)), Henrik Lindman(Uppsala University), Daniel Nyqvist(Karolinska Institutet), Rosa Lauppe(Quantify Research (Sweden))
Cited by 0
Related Papers
Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment
|PLoS ONE|2009|504
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial
|The Lancet|2000|343
Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [<sup>68</sup>Ga]ABY-025 Affibody PET/CT
|Theranostics|2015|269
First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the <sup>111</sup>In-ABY-025 Affibody Molecule
|Journal of Nuclear Medicine|2014|260